Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;86(1):93-105.
doi: 10.1111/bcp.14138. Epub 2019 Nov 21.

Using GRADE methodology to assess innovation of new medicinal products in Italy

Filomena Fortinguerra  1 , Giovanni Tafuri  1 , Francesco Trotta  1 , Antonio Addis  2
Affiliations

Using GRADE methodology to assess innovation of new medicinal products in Italy

Filomena Fortinguerra et al. Br J Clin Pharmacol. 2020 Jan.

Abstract

Aim: In April 2017 the Italian Medicine Agency (AIFA) developed new criteria to grant any new medicinal product with an innovative designation. The aim of this study is to describe this new model and how it works.

Methods: A retrospective descriptive analysis was performed on the results of the assessment process of innovativeness of new medicinal products (or therapeutic indications) based on the AIFA's new innovation criteria (therapeutic need, added therapeutic value and quality of clinical evidence through GRADE methodology) carried out between April 2017 and February 2019 and made publicly available on the AIFA website starting from January 2018.

Results: A total of 37 full reports (22 for oncological indications) explaining the rationale for the AIFA's decision is made publicly available on the agency's website. A total of 12 therapeutic indications (5 oncological) were evaluated as fully innovative, 13 indications (11 oncological) were evaluated as conditionally innovative, while 12 indications (6 oncological) as non-innovative.

Conclusion: The new AIFA innovation criteria resulted in a much more flexible and transparent model to define and assess what constitutes a therapeutic innovation. In particular, the choice of AIFA to use the GRADE methodology to evaluate the quality of clinical evidence within a process of drug innovativeness assessment is essential for the early identification of the discrepancy between the need for patients of a rapid access to innovative therapies and the available clinical data needed to make decisions on drug innovativeness.

Keywords: GRADE; added therapeutic value; drug therapy; innovativeness; therapeutic need.

PubMed Disclaimer

Conflict of interest statement

There are no competing interests to declare.

References

    1. Kesselheim AS, Wang B, Avorn J. Defining "innovativeness" in drug development: a systematic review. Clin Pharmacol Ther. 2013;94(3):336‐348. - PubMed
    1. Kopp C. What is a truly innovative drug? New definition from the International Society of Drug Bulletins. Can Fam Physician. 2002;48:1413‐1415. 1424‐6 - PMC - PubMed
    1. Caprino L, Russo P. Developing a paradigm of drug innovation: an evaluation algorithm. Drug Discov Today. 2006;11(21‐22):999‐1006. - PubMed
    1. Aronson JK, Ferner RE, Hughes DA. Defining rewardable innovation in drug therapy. Nat Rev Drug Discov. 2012;11(4):253‐254. - PubMed
    1. Pease AM, Krumholz HM, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ. 2017;357:j1680. - PMC - PubMed